Lorne Tyrrell, OC, AOE, MD, PhD, FRCPC, FRSC, FCAHS

Professor and Director, Li Ka Shing Institute of Virology; GSK Chair in Virology, Faculty of Medicine & Dentistry - Medical Microbiology and Immunology Dept

Contact Overview Publications

Contact

Professor and Director, Li Ka Shing Institute of Virology; GSK Chair in Virology, Faculty of Medicine & Dentistry - Medical Microbiology and Immunology Dept

Email: lorne.tyrrell@ualberta.ca
Phone: (780) 492-8415
Address: 6010E Katz Group Centre For Research
11315 - 87 Ave NW

Edmonton AB

T6G 2H5

Overview

Area of Study / Keywords

animal models hepatitis B hepatitis C

About

D. Lorne Tyrrell is a Distinguished University Professor at the University of Alberta. He is the Founding Director of the Li Ka Shing Institute of Virology. He has focused his research since 1986 on viral hepatitis. His work on the development of antiviral therapy was supported by CIHR and Glaxo Canada. It resulted in the licensing of the first oral antiviral agent to treat chronic hepatitis B infection - lamivudine - in 1998. Today, lamivudine is licensed in over 200 countries worldwide for the treatment of HBV. He worked with Drs Norm Kneteman and David Mercer to establish a biotech company, KMT Hepatech Inc. based on the first non-primate animal model for HCV. This company was purchased in 2017 by PhoenixBio, but remains in Edmonton.

Dr. Tyrrell was the Dean of the Faculty of Medicine and Dentistry from 1994-2004. Since leaving the Deanship in 2004, Dr. Tyrrell has taken on a number of important board positions in healthcare in Alberta and Canada. These include the Chair of the Gairdner Foundation Board, and member of the Research Advisory Council for the Canadian Institute for Advanced Research. He also has been appointed to the Science Advisory Board to Health Canada. In 2010, he became the Founding Director of the Li Ka Shing Institute of Virology.

For his studies on viral hepatitis, Dr. Tyrrell has received numerous prestigious awards including the Gold Medal of the Canadian Liver Foundation (2000), Officer of the Order of Canada (2002), Alberta Order of Excellence (2000) and Fellow of the Royal Society of Canada (2004). He was inducted into the Canadian Medical Hall of Fame in April 2011 and was awarded the Killam Prize Health Sciences in May 2015.

Since the COVID-19 pandemic, he has worked on antivirals and vaccines for SARS-CoV-2. He is a member of the COVID-19 Vaccine Task Force that advises the Federal Government on the selection of COVID-19 vaccines based on efficacy, safety, and timely availability for Canada.

Featured Publications

The Effect of Deuteration and Homologation of the Lactam Ring of Nirmatrelvir on Its Biochemical Properties and Oxidative Metabolism

Arutyunova E, Belovodskiy A, Chen P, Khan MB, Joyce M, Saffran H, Lu J, Turner Z, Bai B, Lamer T, Young HS, Vederas JC, Tyrrell DL, Lemeiux MJ, Nieman JA

ACS Biom & MNed Chem Au. 2023 November; 10.1021/acsbiomedchemau.3c00039

Analysis of SARS-CoV-2 isolates, namely the Wuhan strain, Delta variant, and Omicron variant, identifies differential immune profiles

Shahbaz S, Bozorgmehr N, Lu J, Osman M, Sligl W, Tyrrell DL, Elahi S

Microbiol Spectr. 2023 September; 10.1128/spectrum.01256-23

Characterization of Monoclonal Antibodies to Measure Cell Surface Protein Levels of Human Interferon-Lambda Receptor 1

de Weerd NA, Ogungbola O, Liu X, Matthews AY, Ismail A, Vivian JP, Lim SS, Tyrrell DL, Putcha N, Skawinski M, Dickensheets H, Lavoie TB, Donnelly RP, Hertzog PJ, Santer DM

J Interferon Cytokine Res. 2023 September; 43 (9):403-413 10.1089/jir.2023.0040

Challenge Inoculum for Hepatitis C Virus Controlled Human Infection Model

Liang TJ, Law JLM, Pietschmann T, Ray SC, Bukh J, Bull R, Chung RT, Tyrrell DL, Houghton M, Rice CM

Clinical Infectious Diseases. 2023 August; 77 (Supplement 3) 10.1093/cid/ciad336

Interferon-treatment accelerates SARS-CoV-2 clearance despite age-related delays in the induction of T cell immunity

Santer DM, Li D, Ghoshe Y, Zahoor MA, Prajapati D, Hansen BE, Tyrrell DLJ, Feld JJ, Gehring AJ

Nature Communications. 2022 November; 13 10.1038/s41467-022-34709-4

Feline coronavirus drug inhibits the main protease of SARS-CoV-2 and blocks virus replication

Wayne Vuong, Muhammad Bashir Khan, Conrad Fischer, Elena Arutyunova, Tess Lamer, Justin Shields, Holly A. Saffran, Ryan T. McKay, Marco J. van BNelkum, Michael A. Joyce, Howard S. Young, D. Lorne Tyrrell, John C. Vederas & Joanne Lemieux

Nature Communications. 2022 September; 10.1038/s41457-020-18096-2

Two DNA vaccines protect against severe disease and pathology due to SARS-CoV-2 in Syrian hamsters

Babuadze G.G., Fausther-Bovendo H., deLaVega M.A., Lillie B., Naghibosadat M., Shahhosseini N., Joyce M.A., Saffran H.A., Lorne Tyrrell D., Falzarano D., Senthilkumaran C., Christie-Holmes N., Ahn S., Gray-Owen S.D., Banerjee A., Mubareka S., Mossman K., Dupont C., Pedersen J., Lafrance M.A., Kobinger G.P., Kozak R.

npj Vaccines. 2022 April; 7 (49):1-11 10.1038/s41541-022-00461-5

On-Site Viral Inactivation and RNA Preservation of Gargle and Saliva Samples Combined with Direct Analysis of SARS-CoV-2 RNA on Magnetic Beads

Liu Y, Kumblathan T, Feng W, Pang G, Tao J, Xu J, Xiao H, Joyce MA, Tyrrell DL, Zhang H, Li XF, Le XC

ACS Measurement Science. 2022 February; 2 doi.org/10.1021/acsmeasuresciau.1c00057

Computational determination of toxicity risks associated with a selection of approved drugs having demonstrated activity against COVID-19

Aminpour M, Miranda-Delgado W, Wacker S, Noskov S, Houghton M, Tyrrell DL, Tuszynski JA

BMC Pharmacology & Toxicology. 2021 October; 22 (61):1-20 doi.org/10.1186/s40360-021-00519-5

Integrating Reverse Transcription Recombinase Polymerase Amplification with CRISPR Technology for One-Tube Assay of RNA. Analytical Chemistry

Feng W, Peng H, Xu J, Liu Y, Pabbaraju K, Tipples G, Joyce MA, Saffran H, Tyrrell DL, Babiuk S, Zhang H, Le XC

ANALYTICAL CHEMISTRY. 2021 September; 93 (37):12808-12816 doi.org/10.1021/acs.analchem.1c03456

SARS-CoV-2 recombinant Receptor-Binding-Domain (RBD) induces neutralizing antibodies against variant strains of SARS-CoV-2 and SARS-CoV-1

Law J, Logan M, Joyce MA, Landi A, Hockman D, Crawford K, Johnson J, LaChance G, Saffran HA, Shields J, Hobart E, Brassard R, Arutyunova E, Pabbaraju K, Croxen M, Tipples G, Lemieux MJ, Tyrrell DL, Houghton M

VACCINE. 2021 September; 39 (40):5769-5779 doi.org/10.1016/j.vaccine.2021.08.081

Peptidomimetic nitrile warheads as SARS-CoV-2 3CL protease inhibitors

Bai B, Arutyunova E, Khan MB, Lu J, Joyce MA, Saffran H, Shields JA, Kandadai AS, Belovodskiy A, Hena M, Vuong W, Lamer T, Young H, Vederas J, Tyrrell DL, Lemieux J and Nieman J

RSC Medicinal Chemistry. 2021 August; 12 (10):1722-1730 doi: 10.1039/D1MD00247C

Peptidomimetic a-acyloxymethylketone warheads with 6-membered lactam P1 glutamine mimic: SARS-CoV-2 3CL protease inhibition, coronavirus antiviral activity and in vitro biological stability

Bai B, Belovodskiy A, Hena M, Kandadai AS, Joyce M, Saffran H, Shields J, Khan M, Arutyunova E, Lu J, Bajwa S, Hockman D, Fischer C, Lamer T, Vuong W, Van Belkum M, Gu Z, Lin F, Du Y, Xu J, Rahim M, Young H, Vederas J, Tyrrell DL, Lemieux MJ, Nieman J

JOURNAL OF MEDICINAL CHEMISTRY. 2021 July; 65 (4):2905-2925 doi: 10.1021/acs.jmedchem.1c00616

CRISPR technique incorporated with single-cell RNA sequencing for studying hepatitis B infection.

Le C, Liu Y, López-Orozc J, Joyce MA, Le XC, Tyrrell DL

ANALYTICAL CHEMISTRY. 2021 July; 93 (31):10756-10761 doi.org/10.1021/acs.analchem.1c02227

N-Terminal finger stabilizes the S1 pocket for the reversible feline drug GC376 in the SARS-CoV-2 Mpro dimer.

Arutyunova E, Khan MB, Fischer C, Lu J, Lamer T, Vuong W, van Belkum MJ, McKay R, Tyrrell DL, Vederas JC, Young HS, Lemieux MJ.

JOURNAL OF MOLECULAR BIOLOGY. 2021 June; 433 (13):167003 doi.org/10.1016/j.jmb.2021.167003

Peginterferon-lambda for the treatment of outpatients with COVID-19: a phase 2, placebo-controlled randomized trial

Feld J*, Kandel C*, Biondi NP*, Kozak RA, Lemieux C, Borgia S, Boggild A, Powis J, McCready J, Tan D, Chan T, Coburn B, Kumar D, Humar A, Chan A, O’Neil B, Noureldin S, Booth J, Hong R, Smookler D, Aleyadeh W, Patel A, Barber B, Casey J. Zahoor A, Hiebert R, Mistry H, Santer D, Tyrrell DLJ, Gleen JS, Gehring AJ, Janssen HLA, Hansen B. *Contributed equally to the work

The Lancet Respiratory Medicine. 2021 May; 9 (5):498-510 doi.org/10.1016/S2213-2600(20)30566-X

Improved SARS-CoV-2 Mpro inhibitors based on feline antiviral drug GC376: structural enhancements, increased solubility, and micellar studies

Vuong W, Fischer C, Khan MB, van Belkum M, Lamer T, Willoughby K, Lu J, Arutyunova E, Joyce MA, Saffran H, Shields J, Young H, Nieman J, Tyrrell DL, Lemieux MJ, Vederas J

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY. 2021 May; 222 doi.org/10.1016/j.ejmech.2021.113584

Erythroid precursors and progenitors suppress adaptive immunity and get invaded by SARS-CoV-2

Shahbaz S, Xu L, Osman M, Sligl W, Shields J, Joyce MA, Tyrrell DLJ, Oyegbami O, and Elahi S.

Stem Cell Reports. 2021 May; 16 10.1101.2020.08.18.255927

Antibodies to neutralizing epitopes synergistically block the interaction of the receptor binding domain of SARS-CoV-2 to ACE 2

Pandey M, Ozberk V, Eskandari S, Shalash A, Joyce MA, Saffran HA, Day CJ, Lepletier A, Spillings BL, Mills J-L, Calcutt A, Fan F, Williams JT, Stanisic DI, Hattingh L, Gerrard J, Skwarczynski M, Mak J, Jennings MP, Toth I, Tyrrell DL, Good MF

Clinical & Translational Immunology. 2021 March; doi: 10.1002/cti2.1260

CRISPR/Cas9 gene editing of hepatitis B virus in chronically infected humanized mice

Stone D, Long KR, De Silva Feelixge HS, Kenkel EJ, Liley RM, Rapp S, Roychoudhury P, Nguyen T, Stensland L, Loprieno M, Weber ND, Le C, Wagoner J, Goecker EA, Tyrrell DLJ, Greninger AL, Huang ML, Polyak SJ, Aubert M, Sagartz JE, Jerome KR

Molecular Therapy-Methods & Clinical Development. 2021 March; 20 doi.org/10.1016/j.omtm.2020.11.014

CRISPR technology incorporating amplification strategies: Molecular assays for nucleic acids, proteins, and small molecules.

Feng W, Newbigging A, Tao J, Cao Y, Peng H, Le C, Wu J, Pag B, Li J, Tyrrell DL, Zhang, H, Le X.

Chemical Science. 2021 February; 12 doi: 10.1039/d0sc06973f

In vitro infection with hepatitis B virus using differentiated human serum culture of Huh7.5-NTCP cells without requiring dimethyl sulfoxide

Le C, Sirajee R, Steenbergen R, Joyce MA, Addison WR, Tyrrell DL

Viruses-Basel. 2021 January; 13 (97) doi.org/10.3390/v13010097

Application of Molecular Dynamics Simulations to the Design of Nucleotide Inhibitors binding to Norovirus Polymerase. Journal of Chemical Information and Modeling

Freedman H, Kundu J, Tchesnokov E, Law J, Nieman J, Schinzai R, Tyrrell DL, Götte M, Houghton M.

Journal of Chemical Information and Modeling. 2020 December; 60 (12):6566-6578 doi: 10.1021/acs.jcim.0c00742

Isothermal amplification and ambient visualization in a single tube for the detection of SARS-CoV-2 using loop-mediated amplification and CRISPR technology

Pang B, Xu J, Liu Y, Peng H, Feng W, Cao Y, Wu J, Xiao H, Pabbaraju K, Tipples G, Joyce MA, Bandi H. Tyrrell DL, Zhang H, Le XC

ANALYTICAL AND BIOANALYTICAL CHEMISTRY. 2020 December; 92 doi: 10.1021/acs.analchem.0c04047

Interferons and viruses induce a novel truncated ACE2 isoform and not the full-length SARS-CoV-2 receptor

Onabajo OO, Banday AR, Stanifer ML, Yan W, Obajemu A, Santer DM, Florez-Vargas O, Piontkivska H, Vargas JM, Ring TJ, Kee C, Doldan P, Tyrrell DL, Mendoza JL, Boulant S, and Prokunina-Olsson L

NATURE GENETICS. 2020 October; 52 https://doi.org/10.1038/s41588-020-00731-9

View additional publications